Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

A Dual Inhibitor Treatment for RA?

Michele B. Kaufman, PharmD, BCGP  |  July 17, 2023

Results

In the study, a total of 101 patients were randomized; approximately 50% had previously used biologic disease-modifying anti-rheumatic drugs (bDMARDs), and approximately 30% of patients had previously used JAK inhibitors. According to the researchers, patient demographics and baseline disease characteristics were similar across treatment groups. 

At week 12, 48.0% of patients in the 10 mg TLL-018 treatment group achieved an ACR50 response (95%; confidence interval [CI]: 28.42–67.58), 65.4% of patients in the 20 mg TLL-018 treatment group achieved an ACR50 response (95%; CI: 47.10–83.67) and 72.0% patients in the 30 mg TLL-018 treatment group achieved an ACR50 response (95%; CI: 54.40–89.60). In the group that received 5 mg of tofacitinib twice daily, 41.7% of patients achieved an ACR50 response (95%; CI: 21.94–61.39). The response rates of both the 20 mg TLL-018 BID treatment group and 30 mg TLL-018 treatment group were statistically superior to the tofacitinib treatment group (P<0.05).

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The proportions of patients achieving clinical remission (i.e., a DAS28-CRP score of <2.6) at week 12 were 39.1% for the 10 mg TLL-018 treatment group, 34.8% for the 20 mg TLL-018 treatment group and 54.5% for the 30 mg TLL-018 treatment group compared with only 17.4% of patients in the tofacitinib treatment group.

bDMARDs: Both the 20 mg and 30 mg doses of TLL-018 demonstrated higher efficacy than tofacitinib in patients who had prior bDMARD use. These patients achieved ACR50 rates of greater than 66%.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Patients on tofacitinib who did not achieve an ACR50 response at week 12 and were switched to 20 mg of TLL-018 twice daily experienced subsequent improved responses (not reported). Specific secondary end point results were not reported.

In patients who received either treatment, the most frequently reported treatment-emergent adverse events were hyperlipidemia and respiratory infection. One case of malignancy was reported in a patient who received tofacitinib. No deaths, venous thromboembolism or major adverse cardiovascular events were observed during the study.

Conclusion

At 20 mg and 30 mg twice-daily doses, TLL-018 demonstrated superior efficacy over 5 mg of tofacitinib twice daily for treating patients with RA. These results suggest that inhibiting TYK-2 in addition to JAK-1 may benefit this patient population.

TLL-018 was well tolerated with no unexpected safety concerns. TLL-018 may prove beneficial in further studies in patients with RA who are difficult to treat. Phase 3 studies are planned in China, but not yet in the U.S. for this indication.3

Page: 1 2 3 | Single Page
Share: 

Filed under:Biologics/DMARDsDrug UpdatesMeeting Reports Tagged with:EULAR 2023

Related Articles

    Tofacitinib with Methotrexate Not Inferior to Adalimumab with Methotrexate

    July 13, 2017

    Highlights from the 2017 EULAR Congress MADRID—Tofacitinib (a JAK inhibitor) used with methotrexate (MTX) is not inferior to adalimumab (a TNF inhibitor) plus MTX in rheumatoid arthritis (RA) patients who’ve had an inadequate response to MTX alone, according to results of a Phase 3B/4 trial presented in a session at the Annual European Congress of…

    EU Approves Tofacitinib Citrate for 2 Pediatric Conditions

    September 8, 2021

    The European Commission approved tofacitinib citrate to treat two pediatric conditions, as well as a prolonged-release version of the medication designed to treat adults with active PsA.

    Effectiveness of Tofacitinib with Methotrexate, Adalimumab Therapy Evaluated in Patients with RA

    September 19, 2017

    MADRID—Tofacitinib (a JAK inhibitor) used with methotrexate (MTX) is not inferior to adalimumab (a TNF inhibitor) in rheumatoid arthritis (RA) patients who’ve had an inadequate response to MTX alone, according to results of a Phase 3B/4 trial presented in a session at the Annual European Congress of Rheumatology (EULAR). The findings came in a one-year…

    Updates on JAK Inhibitor Safety, COVID-19 Vaccination in Immunosuppressed Patients & More

    December 7, 2021

    ACR CONVERGENCE 2021—The ACR Convergence 2021 meeting reflected the continued advancement of science and practical research in the field of rheumatoid arthritis (RA). Among the most important topics this year in RA was the evolution of the risk-benefit profile of Janus kinase (JAK) inhibitors, for which new safety data emerged in a series of related…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences